Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical research stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.

Why Regeneron Pharmaceuticals stock is on investor radar today Regeneron Pharmaceuticals (REGN) is drawing attention after a period in which its share price has moved between negative weekly returns ...

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value ...

What a fantastic six months it’s been for Regeneron. Shares of the company have skyrocketed 47.6%, hitting $774.98. This was partly due to its solid quarterly results, and the performance may have ...

Here is why we believe Regeneron Pharmaceuticals (REGN) stock is worthy of consideration as a value investment. It is presently trading nearly 38% lower than its one-year peak, and is also being ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has drawn renewed market attention following a rating downgrade that contrasts ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best immunotherapy stocks to buy according to hedge funds. RBC Capital reiterated a Hold rating on Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) on Friday reported upbeat fourth-quarter earnings. The company posted adjusted earnings of $11.44 per share, down 5% year-over-year, beating the consensus ...

On 24 February 2026, Regeneron and Sanofi reported that the FDA approved Dupixent for allergic fungal rhinosinusitis in patients aged six and older with prior sino-nasal surgery. This first ...